Mehta R L, Takahashi H, Rudick R A, Knutson D W
J Immunol. 1986 Mar 1;136(5):1765-71.
We studied Fc receptor and C3b receptor (CR1) function on U937 cells, a human monocyte cell line. C3b was incorporated into stable soluble heat aggregates of 125I-IgM (A-IgM) and 125I-IgG (A-IgG) by using functionally pure classical pathway components. C3b incorporation was verified by the ability of aggregates to bind to human red cells and by cosedimentation of 125I and 131I during ultracentrifugation. Cell uptake and degradation of A-IgG X C3b was increased up to twofold compared with A-IgG not containing C3b molecules. However, A-IgG X C3b bound to CR1 after Fc receptors were blocked with nonradiolabeled A-IgG were also not endocytosed and catabolized. Moreover, A-IgM X C3b was bound but not degraded by U937 cells. As expected, uptake of A-IgM without C3b was negligible. CR1-mediated binding of A-IgM X C3b was specifically inhibited both by a murine monoclonal antibody against the human CR1 that blocks C3b binding and by C3b oligomers generated by trypsin activation of C3, but not by monoclonal antibodies against the iC3b receptor (CR3). We conclude that CR1 on U937 cells cause increased binding of A-IgG, and this increased binding leads to increased Fc-mediated endocytosis and catabolism of model immune complexes. However, binding of soluble ligands by CR1 alone, even when binding is multivalent, does not lead to endocytosis and degradation of soluble ligands bearing C3b.
我们研究了人单核细胞系U937细胞上的Fc受体和C3b受体(CR1)功能。通过使用功能纯的经典途径成分,将C3b掺入125I-IgM(A-IgM)和125I-IgG(A-IgG)的稳定可溶性热聚集体中。通过聚集体与人红细胞结合的能力以及超速离心期间125I和131I的共沉降来验证C3b的掺入。与不含C3b分子的A-IgG相比,A-IgG×C3b的细胞摄取和降解增加了两倍。然而,在用非放射性标记的A-IgG阻断Fc受体后与CR1结合的A-IgG×C3b也未被内吞和分解代谢。此外,A-IgM×C3b被U937细胞结合但未被降解。正如预期的那样,不含C3b的A-IgM的摄取可忽略不计。A-IgM×C3b的CR1介导的结合被一种针对人CR1的鼠单克隆抗体特异性抑制,该抗体可阻断C3b结合,也被胰蛋白酶激活C3产生的C3b寡聚体抑制,但不被针对iC3b受体(CR3)的单克隆抗体抑制。我们得出结论,U937细胞上的CR1导致A-IgG结合增加,这种增加的结合导致模型免疫复合物的Fc介导的内吞作用和分解代谢增加。然而,单独由CR1结合可溶性配体,即使结合是多价的,也不会导致带有C3b的可溶性配体的内吞作用和降解。